Complete trial results manuscript of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv.
Read time: 1 mins
Last updated:24th Sep 2021
Published:23rd May 2021
The full results from Novavax’ Phase III, randomized, observer-blinded, placebo-controlled trial conducted in more than 15,000 adults in the United Kingdom have been published in a manuscript posted to the preprint server medRxiv.
The full results from Novavax’ Phase III, randomized, observer-blinded, placebo-controlled trial conducted in more than 15,000 adults in the United Kingdom have been published in a manuscript posted to the preprint server medRxiv. Conclusions state that a two-dose regimen of Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, conferred nearly 90% protection against a blend of prototype and variant COVID-19, demonstrated high efficacy against the B.1.1.7 variant, and demonstrated a reassuring safety profile. The study assessed efficacy during a period when the B.1.1.7 variant strain of the virus was emerging and circulating widely in the United Kingdom. It is now the most widely circulating variant strain of the virus in the United States. Abstract:Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant.:Background : Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant. Methods : A phase III, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-µg doses, 21 days apart, of NVX-CoV2373 or placebo (1:1) across 33 sites in the United Kingdom. The primary efficacy endpoint was virologically confirmed symptomatic Covid-19 with onset 7 days after second vaccination in serologically negative participants.Results : A total of 15,187 participants were randomized, of whom 7569 received NVX-CoV2373 and 7570 received placebo; 27.2% were 65 years or older, 44.7% had comorbidities and 4.2% had baseline serological evidence of SARS-CoV-2. There were 10 cases of Covid-19 among NVX-CoV2373 recipients and 96 cases among placebo recipients, with symptom onset at least 7 days after second vaccination; NVX-CoV2373 was 89.7% (95% confidence interval, 80.2 to 94.6) effective in preventing Covid-19, with no hospitalizations or deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of 96.4% (73.8 to 99.5) and 86.3% (71.3 to 93.5) against the prototype strain and B.1.1.7 variant, respectively. Vaccine efficacy was similar across subgroups, including participants with comorbidities and those ?65 years old. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups. Conclusion : A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.1.7 variant, and had a reassuring safety profile. See-"Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant"-Paul T. Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne,et.al.doi:https://doi.org/10.1101/2021.05.13.21256639.This article is a preprint and has not been peer-reviewed . It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Condition: Coronavirus/COVID-19 Infection